Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease,Accelerate Cognitive Decline,and Modulate Donepezil Response in Mild Cognitively Impaired Subjects
Restricted accessResearch articleFirst published online October 4, 2016
Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease,Accelerate Cognitive Decline,and Modulate Donepezil Response in Mild Cognitively Impaired Subjects
Background: Genetic heterogeneity in amnestic mild cognitively impaired (aMCI) subjects could lead to variations in progression rates and response to cholinomimetic agents. Together with the apolipoprotein E4 (APOE-ɛ4) gene, butyrylcholinesterase (BCHE) has become recently one of the few Alzheimer’s disease (AD) susceptibility genes with distinct pharmacogenomic properties.
Objective: To validate candidate genes (APOE/BCHE) which display associations with age of onset of AD and donepezil efficacy in aMCI subjects.
Methods: Using the Petersen et al. (2005) study on vitamin E and donepezil efficacy in aMCI, we contrasted the effects of BCHE and APOE variants on donepezil drug response using the Alzheimer’s Disease Assessment Score-Cognition (ADAS-Cog) scale. Independently, we assessed the effects of APOE/BCHE genotypes on age of onset and cortical choline acetyltransferase activity in autopsy-confirmed AD and age-matched control subjects.
Results: Statistical analyses revealed a significant earlier age of onset in AD for APOE-ɛ4, BCHE-K*, and APOE-ɛ4/BCHE-K* carriers. Among the carriers of APOE-ɛ4 and BCHE-K*, the benefit of donepezil was evident at the end of the three-year follow-up. The responder’s pharmacogenomic profile is consistent with reduced brain cholinergic activity measured in APOE-ɛ4 and BCHE-K* positive subjects.
Conclusions:APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy. These results clearly emphasize the necessity of monitoring potential pharmacogenomic effects in this population of subjects, and suggest enrichment strategies for secondary prevention trials involving prodromal AD subjects.
GatzM, FratiglioniL, JohanssonB, BergS, MortimerJA, ReynoldsCA, FiskeA, PedersenNL (2005) Complete ascertainment of dementia in the Swedish Twin Registry: The HARMONY study. Neurobiol Aging26, 439–447.
DuboisB, PicardG, SarazinM (2009) Early detection of Alzheimer’s disease: New diagnostic criteria. Dialogues Clin Neurosci11, 135–139.
7.
PetersenRC, DoodyR, KurzA, MohsRC, MorrisJC, RabinsPV, RitchieK, RossorM, ThalL, WinbladB (2001) Current concepts in mild cognitive impairment. Arch Neurol58, 1985–1992.
8.
PetersenRC, SmithGE, IvnikRJ, TangalosEG, SchaidDJ, ThibodeauSN, KokmenE, WaringSC, KurlandLT (1995) Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA273, 1274–1278.
9.
GeulaC, MesulamMM (1989) Cortical cholinergic fibers in aging and Alzheimer’s disease: A morphometric study. Neuroscience33, 469–481.
10.
O’BrienKK, SaxbyBK, BallardCG, GraceJ, HarringtonF, FordGA, O’BrienJT, SwanAG, FairbairnAF, WesnesK, delST, EdwardsonJA, MorrisCM, McKeithIG (2003) Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics13, 231–239.
11.
Darreh-ShoriT, BrimijoinS, KadirA, AlmkvistO, NordbergA (2006) Differential CSF butyrylcholinesterase levels in Alzheimer’s disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis24, 326–333.
12.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
13.
PoirierJ, DavignonJ, BouthillierD, KoganS, BertrandP, GauthierS (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet342, 697–699.
14.
LehmannDJ, WilliamsJ, McBroomJ, SmithAD (2001) Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups. Neuroscience108, 541–554.
15.
RamananVK, RisacherSL, NhoK, KimS, SwaminathanS, ShenL, ForoudTM, HakonarsonH, HuentelmanMJ, AisenPS, PetersenRC, GreenRC, JackCR, KoeppeRA, JagustWJ, WeinerMW, SaykinAJ (2013) APOE and BCHE as modulators of cerebral amyloid deposition: A florbetapir PET genome-wide association study. Mol Psychiatry19, 351–357.
16.
JensenFS, NielsenLR, SchwartzM (1996) Detection of the Plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Heredity46, 26–31.
17.
BartelsCF, JensenFS, LockridgeO, van der SpekAF, RubinsteinHM, LubranoT, La DuBN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet50, 1086–1103.
18.
PodolyE, BruckT, DiamantS, Melamed-BookN, WeissA, HuangY, LivnahO, LangermannS, WilgusH, SoreqH (2008) Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener Dis5, 232–236.
19.
PodolyE, ShalevDE, Shenhar-TsarfatyS, BennettER, BenAE, WilgusH, LivnahO, SoreqH (2009) The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem284, 17170–17179.
20.
GhebremedhinE, ThalDR, SchultzC, BraakH, DellerT (2007) Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages. Acta Neuropathol114, 359–363.
21.
YooHB, LeeHW, ShinS, ParkSW, ChoiJS, JungHY, ChaJ, LeeJM, LeeJY (2014) Butyrylcholinesterase K and Apolipoprotein epsilon4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer’s disease. Curr Alzheimer Res11, 137–144.
22.
WiebuschH, PoirierJ, SevignyP, SchappertK (1999) Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer’s disease. Hum Genet104, 158–163.
23.
McIlroySP, CrawfordVLS, DynanKB, McGleenonBM, VahidassrMD, LawsonJT, PassmoreAP (2000) Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer’s disease in Northern Ireland. J Med Genet37, 182–185.
24.
LehmannDJ, JohnstonC, SmithAD (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet6, 1933–1936.
25.
RayganiAV, ZahraiM, SoltanzadehA, DoostiM, JavadiE, PourmotabbedT (2004) Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer’s disease. Neurosci Lett371, 142–146.
26.
PanegyresPK, MamotteCD, VasikaranSD, WiltonS, FabianV, KakulasBA (1999) Butyrycholinesterase K variant and Alzheimer’s disease. J Neurol246, 369–370.
27.
LehmannDJ, NagyZ, LitchfieldS, BorjaMC, SmithAD (2000) Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer’s disease. Hum Genet106, 447–452.
28.
GhebremedhinE, ThalDR, SchultzC, BraakH (2002) Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett320, 25–28.
29.
LehmannDJ, JohnstonC, SmithAD (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet6, 1933–1936.
30.
SingletonAB, SmithG, GibsonAM, WoodwardR, PerryRH, IncePG, EdwardsonJA, MorrisCM (1998) No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer’s disease. Hum Mol Genet7, 937–939.
31.
MesulamM, GuillozetA, ShawP, QuinnB (2002) Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis9, 88–93.
32.
SmallDH (2001) Biomarkers of Alzheimer’s disease: Bridging the gap between basic science and clinical practice. J Alzheimers Dis3, 257–259.
33.
HuL, WongTP, CoteSL, BellKF, CuelloAC (2003) The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer’s disease-like transgenic mice. Neuroscience121, 421–432.
34.
FilippiniN, ZareiM, BeckmannCF, GalluzziS, BorsciG, TestaC, BonettiM, BeltramelloA, GhidoniR, BenussiL, BinettiG, FrisoniGB (2009) Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE epsilon4 carriers. J Magn Reson Imaging29, 1021–1026.
35.
ChangYL, Fennema-NotestineC, HollandD, McEvoyLK, StrickerNH, SalmonDP, DaleAM, BondiMW (2014) APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer’s disease. Alzheimers Dement10, 336–348.
36.
PerryEK, PerryRH, BlessedG, TomlinsonBE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol4, 273–277.
LaneR, HeY, MorrisC, LeverenzJB, EmreM, BallardC (2009) BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord24, 392–400.
39.
LaneR, FeldmanHH, MeyerJ, HeY, FerrisSH, NordbergA, rreh-ShoriT, SoininenH, PirttilaT, FarlowMR, SfikasN, BallardC, GreigNH (2008) Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenet Genomics18, 289–298.
PoirierJ, MironJ, PicardC (2014) Pharmacogenomic approaches to the treatment of sporadic Alzheimer disease using cholinomimetic agents., In Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric DiseaseRosenbergRN, PascualJM Eds. Academic PressNew York, pp. 51–60.
42.
LaneRM, HeY (2009) Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias. Med Hypotheses73, 230–250.
43.
BullockR, BergmanH, TouchonJ, GambinaG, HeY, NagelJ, LaneR (2006) Effect of age on response to rivastigmine or donepezil in patients with Alzheimer’s disease. Curr Med Res Opin22, 483–494.
44.
BullockR, TouchonJ, BergmanH, GambinaG, HeY, RapatzG, NagelJ, LaneR (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin21, 1317–1327.
45.
BlesaR, BullockR, HeY, BergmanH, GambinaG, MeyerJ, RapatzG, NagelJ, LaneR (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer’s disease. Pharmacogenet Genomics16, 771–774.
46.
PetersenRC, ThomasRG, GrundmanM, BennettD, DoodyR, FerrisS, GalaskoD, JinS, KayeJ, LeveyA, PfeifferE, SanoM, van DyckCH, ThalLJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med352, 2379–2388.
47.
KhachaturianZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol42, 1097–1105.
48.
LabergeAM, MichaudJ, RichterA, LemyreE, LambertM, BraisB, MitchellGA (2005) Population history and its impact on medical genetics in Quebec. Clin Genet68, 287–301.
49.
GagnonA, ToupanceB, TremblayM, BeiseJ, HeyerE (2006) Transmission of migration propensity increases genetic divergence between populations. Am J Phys Anthropol129, 630–636.
50.
BetardC, KesslingAM, RoyM, ChamberlandA, Lussier-CacanS, DavignonJ (1992) Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet88, 529–536.
51.
AubertI, AraujoDM, CecyreD, RobitailleY, GauthierS, QuirionR (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases. J Neurochem58, 529–541.
52.
TucekS, ZelenaJ, GeI, VyskocilF (1978) Choline acetyltransferase in transected nerves, denervated muscles and Schwann cells of the frog: Correlation of biochemical electron microscopical and electrophysiological observations. Neuroscience3, 709–724.
53.
RoyoJL, HidalgoM, RuizA (2007) Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protoc2, 1734–1739.
54.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
55.
PoirierJ, DavignonJ, BouthillierD, KoganS, BertrandP, GauthierS (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet342, 697–699.
56.
PodolyE, BruckT, DiamantS, Melamed-BookN, WeissA, HuangY, LivnahO, LangermannS, WilgusH, SoreqH (2008) Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener Dis5, 232–236.
57.
PetersenRC, ThomasRG, GrundmanM, BennettD, DoodyR, FerrisS, GalaskoD, JinS, KayeJ, LeveyA, PfeifferE, SanoM, van DyckCH, ThalLJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med352, 2379–2388.
58.
Simão-SilvaDP, BertolucciPH, de LabioRW, PayãoSL, Furtado-AlleL, SouzaRL (2013) Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer’s disease in a Brazilian population. Chem Biol Interact203, 358–360.
59.
WangZ, JiangY, WangX, DuY, XiaoD, DengY, WangJ (2015) Butyrylcholinesterase K variant and Alzheimer’s disease risk: A meta-analysis. Med Sci Monit21, 1408–1413.
BizzarroA, GuglielmiV, LomastroR, ValenzaA, LauriaA, MarraC, SilveriMC, TizianoFD, BraheC, MasulloC (2010) BuChE K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia. J Neural Transm117, 377–383.
62.
KurzA, VanBB (2004) Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: A review based on meta-analyses by the cochrane collaboration. Dement Geriatr Cogn Disord18, 217–226.
63.
FeldmanHH, FerrisS, WinbladB, SfikasN, MancioneL, HeY, TekinS, BurnsA, CummingsJ, delST, InzitariD, OrgogozoJM, SauerH, ScheltensP, ScarpiniE, HerrmannN, FarlowM, PotkinS, CharlesHC, FoxNC, LaneR (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: The InDDEx study. Lancet Neurol6, 501–512.
64.
BartelsCF, JensenFS, LockridgeO, van der SpekAF, RubinsteinHM, LubranoT, LaDu BN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet50, 1086–1103.
65.
Darreh-ShoriT, SiaweshM, MousaviM, AndreasenN, NordbergA (2012) Apolipoprotein epsilon4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer’s disease. J Alzheimers Dis28, 443–458.
66.
TangMX, JacobsD, SternY, MarderK, SchofieldP, GurlandB, AndrewsH, MayeuxR (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet348, 429–432.
67.
StrittmatterWJ, WeisgraberKH, HuangDY, DongLM, SalvesenGS, Pericak-VanceM, SchmechelD, SaundersAM, GoldgaberD, RosesAD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A90, 8098–8102.
68.
de LeonMJ, ConvitA, WolfOT, TarshishCY, DeSantiS, RusinekH, TsuiW, KandilE, SchererAJ, RocheA, ImossiA, ThornE, BobinskiM, CaraosC, LesbreP, SchlyerD, PoirierJ, ReisbergB, FowlerJ (2001) Prediction of cognitive decline in normal elderly subjects with 2-[F-18]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A98, 10966–10971.
69.
BizzarroA, MarraC, AcciarriA, ValenzaA, TizianoFD, BraheC, MasulloC (2005) Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord20, 254–261.
70.
ChoiSH, KimSY, NaHR, KimBK, YangDW, KwonJC, ParkMY (2008) Effect of ApoE genotype on response to donepezil in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord25, 445–450.
71.
PetersenRC, ThomasRG, GrundmanM, BennettD, DoodyR, FerrisS, GalaskoD, JinS, KayeJ, LeveyA, PfeifferE, SanoM, van DyckCH, ThalLJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med352, 2379–2388.
